imatinib mesylate has been researched along with Cerebrovascular Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carreon, D; Doan, C; Durrant, LM; Kim, D; Manaenko, A; McCoy, L; Obenaus, A; Pearce, WJ; Tang, J; Zhang, JH | 1 |
| Gastl, G; Geissler, K; Greil, R; Hantschel, O; Lang, A; Linkesch, W; Lion, T; Petzer, AL; Pittermann, E; Pleyer, L; Thaler, J; Valent, P; Wolf, D | 1 |
| Bessler, WK; Clapp, DW; Conway, SJ; Horn, WE; Ingram, DA; Lasater, EA; Li, F; Mead, LE | 1 |
1 review(s) available for imatinib mesylate and Cerebrovascular Disorders
| Article | Year |
|---|---|
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.
Topics: Antineoplastic Agents; Benzamides; Cerebrovascular Disorders; Clinical Trials as Topic; Comorbidity; Contraindications; Diabetes Mellitus; Drug Administration Schedule; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Selection; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2012 |
2 other study(ies) available for imatinib mesylate and Cerebrovascular Disorders
| Article | Year |
|---|---|
Imatinib attenuates cerebrovascular injury and phenotypic transformation after intracerebral hemorrhage in rats.
Topics: Animals; Cerebral Arteries; Cerebral Hemorrhage; Cerebrovascular Circulation; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Imatinib Mesylate; Male; Phenotype; Rats; Rats, Sprague-Dawley; Receptors, Platelet-Derived Growth Factor; Treatment Outcome | 2016 |
Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway.
Topics: Animals; Antineoplastic Agents; Arterial Occlusive Diseases; Benzamides; Cardiovascular Diseases; Carotid Arteries; Cell Proliferation; Cerebrovascular Disorders; Disease Models, Animal; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Genes, Neurofibromatosis 1; Imatinib Mesylate; Mice; Mice, Mutant Strains; Neurofibromatosis 1; Piperazines; Pyrimidines; Tunica Intima | 2008 |